Tips for talking to your doctor

Only you and your doctor can decide if Somatuline^® Depot (lanreotide) Injection is the right acromegaly treatment for you. Print out a list of questions to ask when you talk to your healthcare professional.

A simple, effective treatment for people with acromegaly

Take a different route:
Somatuline^® Depot (lanreotide) Injection

Acromegaly occurs when your body creates too much of substances known as growth hormones and growth factors. Somatuline^® Depot (lanreotide) Injection is a medical treatment for acromegaly that decreases the effects of those substances and helps your body control acromegaly.

Somatuline^® Depot (lanreotide) Injection is different from other medical treatments for acromegaly, and the differences are simple:

Single, ready-to-use, prefilled syringe
Simple, easy injection procedure

Learn more about treating acromegaly with Somatuline^® Depot (lanreotide) Injection.

View our injection video

Somatuline^® Depot (lanreotide) Injection is injected in an easy, two-step injection process. Learn more about how easy it is to inject Somatuline^® Depot (lanreotide) Injection.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT (LANREOTIDE) INJECTION IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

Tips for talking to your doctor

Take a different route: Somatuline® Depot (lanreotide) Injection

View our injection video

IMPORTANT SAFETY INFORMATION

Take a different route:
Somatuline^® Depot (lanreotide) Injection